{"id":"NCT01697696","sponsor":"Novartis Pharmaceuticals","briefTitle":"Long Term Safety Study of NVA237 vs QAB149 in COPD Patients","officialTitle":"A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2014-11","completion":"2014-11","firstPosted":"2012-10-02","resultsPosted":"2016-03-16","lastUpdate":"2016-03-16"},"enrollment":511,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"NVA237","otherNames":[]},{"type":"DRUG","name":"Long-acting beta 2-agonist (LABA)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"NVA237 dose 1","type":"EXPERIMENTAL"},{"label":"Long-acting beta 2-agonist (LABA)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to provide long term safety data of NVA237. This study will assess the safety and tolerability of a single dose strength of NVA237.","primaryOutcome":{"measure":"Percentage of Participants Reporting Safety and Tolerability in Terms of Adverse Event (AE) Reporting Rate","timeFrame":"52 weeks","effectByArm":[{"arm":"NVA237","deltaMin":77.3,"sd":null},{"arm":"QAB149","deltaMin":77,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":61,"countries":["United States"]},"refs":{"pmids":["27215502"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":251},"commonTop":["CHRONIC OBSTRUCTIVE PULMONARY DISEASE","NASOPHARYNGITIS","COUGH","UPPER RESPIRATORY TRACT INFECTION","VIRAL UPPER RESPIRATORY TRACT INFECTION"]}}